Grabenstein JD - Search Results

1

Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Ciprero KL, Marchese RD, Richard P, Baudin M, Sterling TM, Manoff SB, Radley D, Stek JE, Soubeyrand B, Grabenstein JD, Samson SI, Musey LK. Ciprero KL, et al. Among authors: grabenstein jd. Hum Vaccin Immunother. 2016 Aug 2;12(8):2135-2141. doi: 10.1080/21645515.2016.1156270. Epub 2016 Mar 22. Hum Vaccin Immunother. 2016. PMID: 27002793 Free PMC article.

2

Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults.

Grabenstein JD, Musey LK. Grabenstein JD, et al. Vaccine. 2014 May 1;32(21):2399-405. doi: 10.1016/j.vaccine.2014.02.096. Epub 2014 Mar 14. Vaccine. 2014. PMID: 24637174 Review.

3

Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.

Grabenstein JD, Manoff SB. Grabenstein JD, et al. Vaccine. 2012 Jun 22;30(30):4435-44. doi: 10.1016/j.vaccine.2012.04.052. Epub 2012 Apr 26. Vaccine. 2012. PMID: 22542818 Review.

4

Pneumococcal vaccines in adults: assessing the evolving evidence.

Grabenstein JD, Manoff SB. Grabenstein JD, et al. Vaccine. 2011 Aug 26;29(37):6149-54. doi: 10.1016/j.vaccine.2011.06.116. Epub 2011 Jul 16. Vaccine. 2011. PMID: 21763386 No abstract available.

5

Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake.

Grabenstein JD, Weber DJ. Grabenstein JD, et al. Clin Infect Dis. 2014 Mar;58(6):854-64. doi: 10.1093/cid/cit800. Epub 2013 Dec 15. Clin Infect Dis. 2014. PMID: 24344141 Review.

6

A century of pneumococcal vaccination research in humans.

Grabenstein JD, Klugman KP. Grabenstein JD, et al. Clin Microbiol Infect. 2012 Oct;18 Suppl 5:15-24. doi: 10.1111/j.1469-0691.2012.03943.x. Epub 2012 Aug 6. Clin Microbiol Infect. 2012. PMID: 22882735 Free article. Review.

7

Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic.

Dhankhar P, Grabenstein JD, O'Brien MA, Dasbach EJ. Dhankhar P, et al. Among authors: grabenstein jd. Clin Ther. 2010 Aug;32(8):1501-16. doi: 10.1016/j.clinthera.2010.07.019. Clin Ther. 2010. PMID: 20728763

8

Cost-effectiveness of pneumococcal vaccines for adults in the United States.

Chen J, O'Brien MA, Yang HK, Grabenstein JD, Dasbach EJ. Chen J, et al. Among authors: grabenstein jd. Adv Ther. 2014 Apr;31(4):392-409. doi: 10.1007/s12325-014-0115-y. Epub 2014 Apr 10. Adv Ther. 2014. PMID: 24718851 Free PMC article.

9

Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults.

Grabenstein JD. Grabenstein JD. Clin Infect Dis. 2012 Jul;55(2):255-8. doi: 10.1093/cid/cis354. Epub 2012 Apr 11. Clin Infect Dis. 2012. PMID: 22495543 No abstract available.

10

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.

Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Ogilvie I, et al. Among authors: grabenstein jd. Vaccine. 2009 Aug 6;27(36):4891-904. doi: 10.1016/j.vaccine.2009.05.061. Epub 2009 Jun 9. Vaccine. 2009. PMID: 19520205 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page